Summary of the HESI Consortium Studies Exploring Circulating Inhibin B as a Potential Biomarker of Testis Damage in the Rat
Article first published online: 30 JAN 2013
© 2013 Wiley Periodicals, Inc.
Birth Defects Research Part B: Developmental and Reproductive Toxicology
Special Issue: Part B: Developmental and Reproductive Toxicology
Volume 98, Issue 1, pages 110–118, February 2013
How to Cite
Chapin, R., Weinbauer, G., Thibodeau, M. S., Sonee, M., Saldutti, L. P., Reagan, W. J., Potter, D., Moffit, J. S., Laffan, S., Kim, J. H., Goldstein, R. A., Erdos, Z., Enright, B. P., Coulson, M. and Breslin, W. J. (2013), Summary of the HESI Consortium Studies Exploring Circulating Inhibin B as a Potential Biomarker of Testis Damage in the Rat. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 98: 110–118. doi: 10.1002/bdrb.21041
- Issue published online: 5 FEB 2013
- Article first published online: 30 JAN 2013
- Manuscript Accepted: 12 DEC 2012
- Manuscript Received: 28 NOV 2012
- environmental issues;
The Developmental and Reproductive Toxicity Technical Committee of the Health and Environmental Sciences Institute hosted a working consortium of companies to evaluate a new commercially available analytic assay for Inhibin B in rat serum or plasma. After demonstrating that the kit was stable and robust, the group performed a series of independent pathogenesis studies (23 different compound/investigator combinations) designed to examine the correlation between the appearance of lesions in the testis and changes in circulating levels of Inhibin B. These studies were reported individually in the previous articles in this series (this issue), and are discussed in this paper. For roughly half of these exposures, lesions appeared well before Inhibin B changed. A few of the studies showed a good correlation between seminiferous tubule damage and reduced circulating Inhibin B levels, while for seven exposures, circulating Inhibin B was reduced with no detectable alteration in testis histology. Whether this indicates a prodromal response or a false-positive signal will require further investigation. These exceptions could plausibly suggest some value of circulating Inhibin B as a useful biomarker in some circumstances. However, for roughly half of these exposures, Inhibin B appeared to be a lagging biomarker, requiring significant damage to the seminiferous tubules before a consistent and credible reduction in circulating levels of Inhibin B was observed.